Actinium Pharmaceuticals, Inc. to Present at EMIT Targeted Radiotherapy Conference
NEW YORK, Jan. 28, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, (OTC BB: CTVN), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, reported today that the program of the EMIT: Targeted Radiotherapy conference will feature three presentations devoted to Actinium Pharmaceuticals' clinical programs and technology platform. These presentations will address broadening use of radiolabeled monoclonal antibodies for Hematopoietic Stem Cell Transplantation (HSCT) preparation in various indications; rationale for and prospects of a pivotal study of Iomab-B in relapsed and refractory acute myeloid leukemia (AML) patients; and successfully combining Actimab-A and low dose chemotherapy in front line treatment of older AML patients.
"These presentations demonstrate again both the progress we are making and the interest our product candidates and platforms elicit in the clinic for AML patients in particular," said Jack Talley, president and chief executive officer of Actinium. "We intend to intensify our clinical programs this year and look forward to announcing additional milestones."
The first Actinium program related presentation at this year's EMIT conference entitled "Radioimmunotherapy for Hematopoietic Cell Transplantation of Leukemia and Lymphoma: Emerging Therapy and Future Approaches" will focus on the expanding use in clinical trials of the CD45 targeting monoclonal antibody BC8 labeled with various radioisotopes for optimal match to the cancer being treated in the context of HSCT. The second presentation entitled "Laying the Foundation for Stem Cell Transplantation with RIT for Enhanced Therapeutic Benefit" will focus on the unmet medical need of treating relapsed and refractory AML patients. The third presentation "Targeted Alpha Particle Immunotherapy for Acute Myeloid Leukemia" will highlight results of front line treatment of older newly diagnosed AML patients.
The following are the dates and times of the above referenced presentations:
January 30, 2013, 9.00 am: "Radioimmunotherapy for Hematopoietic Cell Transplantation of Leukemia and Lymphoma: Emerging Therapy and Future Approaches", presenter: John Pagel, MD, Associate Member, Clinical Research Division, Fred Hutchinson Cancer Center
January 31, 2013, 1.30 pm: "Laying the Foundation for Stem Cell Transplantation with RIT for Enhanced Therapeutic Benefit", presenter: Dragan Cicic, MD, COO & CMO, Actinium Pharmaceuticals
January 31, 2013, 2.00 pm: "Targeted Alpha Particle Immunotherapy for Acute Myeloid Leukemia", Joseph Jurcic, MD, Chief, Leukemia Services, New York Presbyterian/Columbia
The above referenced oral presentations will take place at the One Washington Circle Hotel, One Washington Circle, N.W. Washington, D.C. 20037.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. is a New York, New York based biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 isotopes in association with monoclonal antibodies. The Company also develops other radiopharmaceuticals for select applications.
For more information:
Visit our web site www.actiniumpharmaceuticals.comor contact:
Jack Talley, CEO
Actinium Pharmaceuticals Inc.
Tel: (646) 459-4201
E-mail: actimaba@actiniumpharmaceuticals.com
Investors:
Jeff Ramson
ProActive Capital Group, LLC
Tel: (646) 863-6341
E-mail: jramson@proactivecrg.com
www.proactivecrg.com
Media:
Dennis S. Dobson Jr., 203-258-0159
Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
SOURCE Actinium Pharmaceuticals, Inc.